スタッフ・認定医・専門医紹介

教授秋山 佳之 

経歴2024年4月より現職
専門尿路悪性腫瘍の低侵襲手術、間質性膀胱炎の治療研究開発 
所属学会日本泌尿器科学会、日本泌尿器内視鏡・ロボティクス学会、日本内視鏡外科学会、日本泌尿器腫瘍学会、日本癌治療学会、日本排尿機能学会、日本間質性膀胱炎研究会、日本老年泌尿器科学会 
取得専門医日本泌尿器科学会/日本専門医機構 泌尿器科専門医・指導医、日本泌尿器内視鏡・ロボティクス学会 腹腔鏡技術認定医、日本内視鏡外科学会 技術認定医（泌尿器腹腔鏡）、日本泌尿器内視鏡・ロボティクス学会 泌尿器ロボット支援手術プロクター[膀胱・前立腺、副腎・腎（尿管）]、日本がん治療認定医機構 がん治療認定医、日本排尿機能学会 排尿機能専門医 

受賞

  1. Delegates choice Award for open discussion posters: Pain and Sexual dysfunction. The 44th International Continence Society (ICS) annual meeting (2014年)
  2. 第16回Asahi Kasei Pharma Urological Academy研究助成 優秀テーマ (2016年)
  3. Best Basic Science Abstract Award. The 46th International Continence Society (ICS) annual meeting (2016 年)
  4. 第23回日本排尿機能学会 河邉賞　(2016年)
  5. 第26回泌尿器科分子・細胞研究会 研究奨励賞（口演部門）（2017年）
  6. 第42回難病医学研究財団　医学研究奨励助成（2017年）
  7. 第105回日本泌尿器科学会総会 総会賞（2017年）　
  8. 第106回日本泌尿器科学会総会 総会賞（2018年）
  9. Best Abstract Award (Second Prize for the Best Abstract in Non-Oncology). The 35th Annual EAU Congress of the European Association of Urology (2020年)
  10. BEST IN CATEGORY PRIZE (BEST BASIC SCIENCE) . The 50th International Continence Society (ICS) annual meeting (2020年)
  11. Best Reviewer Award for 2020, Lower Urinary Tract Symptoms（2021年）
  12. 第109回日本泌尿器科学会総会 総会賞（2021年）
  13. 第110回日本泌尿器科学会総会 International Session Award（2023年）
  14. International Journal of Urology (IJU) Most Cited Article Award of the Year 2021（2023年）
  15. International Journal of Urology (IJU) Most Cited Article Award of the Year 2022（2024年）
  16. Best Doctors in Japan（2024年）

主要論文 

  1. Hakozaki Y, Yamada Y, Fujimura T, Kimura N, Sasaki K, Maki K, Sugimoto K, Izumi T, Kaneko J, Urabe F, Tokunaga M, Fujii Y, Kamei J, Kawai T, Taguchi S, Akiyama Y, Yamada D, Kume H. Novel clipping procedure for preventing post-operative inguinal hernia in robot-assisted radical prostatectomy。Int J Urol. [Online ahead of print]
  2. Noda M, Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Yamashita H, Nakagawa K, Abe O, Fukuhara H, Kume H. Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis. Strahlenther Onkol. 2024 [Online ahead of print]
  3. Miyakawa J, Yamada Y, Hakozaki Y, Makino K, Kamei J, Taguchi S, Kawai T, Akiyama Y, Yamada D, Kume H. Comparison of PDD-TURBT alone versus conventional TURBT plus intravesical BCG therapy: a propensity-score matching study. Photodiagnosis Photodyn Ther. [Online ahead of print]
  4. Kimura N, Yamada Y, Hakozaki Y, Kaneko J, Kamei J, Taguchi S, Akiyama Y, Yamada D, Fujimura T, Kume H. Upper extremity contact pressure measurement in robot-assisted pelvic surgery. J Robot Surg. 2024; 18: 179.
  5. Yamada Y, Fujii Y, Kakutani S, Kimura N, Sugimoto K, Hakozaki Y, Sugihara T, Takeshima Y, Kawai T, Nakamura M, Kamei J, Taguchi S, Akiyama Y, Sato Y, Yamada D, Urabe F, Miyazaki H, Enomoto Y, Fukuhara H, Nakagawa T, Fujimura T, Kume H. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy. Sci Rep. 2024; 14: 7607.
  6. Akiyama Y*, Niimi A, Nomiya A, Taguchi S, Yamada Y, Sato Y, Kawai T, Yamada D, Kume H, Homma Y. Efficacy and safety of intravesical dimethyl sulfoxide treatment for patients with refractory Hunner-type interstitial cystitis: real-world data post-official approval in Japan. Int J Urol. 2024; 31: 111-118.
  7. Akiyama Y*, Harada K, Miyakawa J, Kreder KJ, O’Donnell MA, Maeda D, Katoh H, Hori M*, Owari K, Futami K, Ishikawa S, Ushiku T, Kume H, Homma Y, and Luo Y*. Th1/17 polarization and potential treatment by an anti-interferon-γ DNA aptamer in Hunner-type interstitial cystitis. iScience. 2023; 26: 108262.
  8. Akiyama Y*, Niimi A, Nomiya A, Taguchi S, Yamada Y, Sato Y, Yamada D, Maeda D, Ushiku T, Kume H, Homma Y. Efficacy and safety of low-dose oral prednisolone for patients with refractory Hunner-type interstitial cystitis. Eur Urol Open Sci. 2023; 56: 1-8.
  9. Akiyama Y, Sonehara K, Maeda D, Katoh H, Naito T, Yamamoto K, Biobank Japan Project, Morisaki T, Ishikawa S, Ushiku T, Kume H, Homma Y, Okada Y. Genome-wide association analysis identifies susceptibility loci within the major histocompatibility complex region for Hunner-type interstitial cystitis. Cell Rep Med. 2023; 4: 101114.
  10. Iwaki T, Akiyama Y*, Nosato H, Kinjo M, Niimi A, Taguchi S, Yamada Y, Sato Y, Kawai T, Yamada D, Sakanashi H, Kume H, Homma Y, Fukuhara H. Deep learning models for cystoscopic recognition of Hunner lesion in interstitial cystitis. Eur Urol Open Sci. 2023; 49: 44-50.
  11. Kawai T, Taguchi S, Nozaki K, Kimura N, Oshina T, Iwaki T, Matsui H, Niimi A, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Kaneko T, Sawayanagi S, Nakayama H, Minamimoto R, Yamashita H, Miyazaki H, Fujimura T, Nakagawa T, Kume H. Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer. Prostate Int. 2023; 11: 239-246.
  12. Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. Int J Urol. 2023; 30: 1180-1186.
  13. Hoshina H, Taguchi S, Suyama H, Kishitani K, Akiyama Y, Yamada Y, Sato Y, Yamada D, Akiba N, Kumasawa K, Mori-Uchino M, Osuga Y, Kume H. Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during pregnancy: a case report. BMC Urology. 2023; 23: 125.
  14. Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. Immunotherapy 2023; 15: 827-837.
  15. Hakozaki Y, Yamada Y, Takeshima Y, Kawai T, Nakamura M, Iwaki T, Teshima T, Kinoshita Y, Taguchi S, Akiyama Y, Sato Y, Yamada D, Suzuki M, Kume H. Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients. Sci Rep. 2023; 13: 2672.
  16. Kurano M, Sumitani M, Akiyama Y, Yamada M, Fujimura D, Yamaki S, Kano K, Aoki J, Hayakawa K, Takahashi T, Hirai T, Okawa A, Kume H, Ogata T, Tanaka S, Chikuda H, Yatomi Y. Usefulness of lysophosphatidylcholine measurement in the cerebrospinal fluid for　differential diagnosis of neuropathic pain : possible introduction into clinical laboratory testing. Clini Chim Acta. 2023; 541: 117249.
  17. Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Taguchi S, Tabata M, Kaneko T, Ishikawa A, Miyazaki H, Kondo Y, Matsumoto A, Naito A, Hikatsu M, Fujii Y, Akiyama Y, Yamada Y, Sato Y , Nomiya A, Yamada D, Murata T, Suzuki M, Enomoto Y, Nishimatsu H, Takeuchi T, Tanaka Y, Kume H. Subclassification of pT3 upper tract urothelial carcinoma: A multicenter retrospective study. World J Urol. 2023; 41: 767-776.
  18. Akiyama Y*, Niimi A, Igawa Y, Nomiya A, Yamada Y, Sato Y, Kawai T, Yamada D, Kume H, Homma Y. Cystectomy for patients with Hunner type interstitial cystitis at a tertiary referral center in Japan. Low Urin Tract Symptoms. 2022; 14: 102-108.
  19. Akiyama Y*, Miyakawa J, O’Donnell MA, Kreder KJ, Luo Yi, Maeda D, Ushiku T, Kume H, Homma Y. Overexpression of HIF1α in Hunner Lesions of Interstitial Cystitis: Pathophysiological Implications. J Urol. 2022; 207: 635-646.
  20. Akiyama Y*, Miyakawa J, O’Donnell MA, Kreder KJ, Luo Yi, Maeda D, Ushiku T, Kume H, Homma Y. Reply by Authors. J Urol. 2022; 207: 646.
  21. Oshina T, Taguchi S, Miyakawa J, Akiyama Y, Sato Y, Kawai T, Fukuhara H, Nakagawa T, Kume H. Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction. Jpn J Clin Oncol. 2022; 52: 65-72.
  22. Kishitani K, Yoda K, Taguchi S, Suyama H, Hoshina H, Akiyama Y, Yamada Y, Sato Y, Yamada D, Kume H. Left–right reversal of the testes within the scrotum: An extremely rare variant of testicular ectopia. IJU Case Rep. 2022; 6: 56-59.
  23. Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Yamamoto S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuhara H, Takahashi S, Kume H. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020). Int J Urol. 2022; 29: 1462-1469.
  24. Nakamura M, Yamada Y, Sato Y, Honda K, Yamada D, Kawai T, Akiyama Y, Suzuki M, Kume H. Preservation of pelvic floor muscles contributes to early continence recovery after robot-assisted radical prostatectomy. PLoS One. 2022; 17: e0275792.
  25. Takeshima Y, Yamada Y, Takemura K, Kimura N, Hakozaki Y, Miyakawa J, Taguchi S, Akiyama Y, Sato Y, Kawai T, Yamada D, Fujimura T, Kume H. The association between the parameters of uroflowmetry and lower urinary tract symptoms in prostate cancer patients after robot-assisted radical prostatectomy. PLoS One. 2022; 17: e0275069.
  26. Hakozaki Y, Yamada Y, Kawai T, Nakamura M, Takeshima Y, Iwaki T, Teshima T, Kinoshita Y, Fujii Y, Akiyama Y, Sato Y, Yamada D, Suzuki M, Kashiwagi-Hakozaki M, Ushiku T, Kume H. Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer. Sci Rep. 2022; 12:16202.
  27. Sugimoto K, Taguchi S, Kishitani K, Kawai T, Masuda K, Nakamura Y, Kinjo M, Tambo M, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Fukuhara H, Kume H. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma. BMC Urol. 2022; 22: 177.
  28. Kimura N, Yamada Y, Takeshima Y, Otsuka M, Akamatsu N, Hakozaki Y, Miyakawa J, Sato Y, Akiyama Y, Yamada D, Fujimura T, Kume H. The ‘prostate-muscle index’: a simple pelvic cavity measurement predicting estimated blood loss and console time in robot-assisted radical prostatectomy. Sci Rep. 2022; 12: 11945.
  29. Teshima T, Kobayashi Y, Kawai T, Kushihara Y, Nagaoka K, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Tanaka N, Tsunoda T, Kume H, Kakimi K. Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma. Oncol Lett. 2022; 24: 265.
  30. Makino K, Sato Y, Takenaka R, Yamashita H, Akiyama Y, Yamada Y, Nakamura M, Kawai T, Yamada D, Suzuki M, Kume H. Cumulative Incidence and Clinical Risk Factors of Radiation Cystitis after Radiotherapy for Prostate Cancer. Urol Int. 2022; 15: 1-7.
  31. Akiyama Y*. Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives. Diagnostics (Basel). 2021; 11: 2238.
  32. Akiyama　Y*, Zaitsu M, Watanabe D, Yoshimura I, Niimi A, Nomiya A, Yamada Y, Sato Y, Nakamura M, Kawai T, Yamada D, Suzuki M, Kume H, Homma Y. Relationship between the frequency of electrocautery of Hunner lesions and changes in bladder capacity in patients with Hunner type interstitial cystitis. Scientific Reports. 2021; 11: 105.
  33. Akiyama Y*, Yao JR, Kreder KJ, O’Donnell MA, Lutgendorf SK, Lyu D, Maeda D, Kume H, Homma Y, and Luo Y*. Autoimmunity to urothelial antigen causes bladder inflammation, pelvic pain and voiding dysfunction: a novel animal model for Hunner type interstitial cystitis. Am J Physiol Renal Physiol. 2021; 320: F174-F182.
  34. Akiyama Y. Editorial Comment from Dr Akiyama to Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunner’s lesion and grade 3 glomerulation might be different from other types of patients. Int J Urol. 2021; 28: 831.
  35. Takeshima Y, Yamada Y, Teshima T, Fujimura T, Kakutani S, Hakozaki Y, Kimura N, Akiyama Y, Sato Y, Kawai T, Yamada D, Kume H. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy. BMC Cancer. 2021; 21: 501.
  36. Noda M, Nakamura M, Kawai T, Sato Y, Yamada Y, Akiyama Y, Yamada D, Suzuki M, Kume H. Early recurrence of bladder cancer in the colon after robot-assisted radical cystectomy: Disappearance following dose-dense methotrexate, vinblastine, doxorubicin and cisplatin treatment. IJU Case Rep. 2021; 4: 429-432.
  37. Kakutani S, Takeshima Y, Yamada Y, Fujimura T, Nagamoto S, Enomoto Y, Hakozaki Y, Kimura N, Teshima T, Akiyama Y, Sato Y, Kawai T, Yamada D, Kume H. Clinical significance and risk factors of urethrovesical anastomotic urinary leakage following robot-assisted radical prostatectomy: a multi-institutional study. BMC Urol. 2021; 21: 75.
  38. Yamada D, Kawai T, Sato Y, Yamada Y, Akiyama Y, Miyakawa J, Takahashi S, Kume H. Trends in prostate cancer diagnosis during the COVID-19 crisis: A report from one high-volume Japanese center. GHM Open. 2021; 1: 28-30.
  39. Kurokawa Y, Kawai T, Miyakawa J, Makise N, Akiyama Y, YamadaY, Sato Y, Yamada D, Ushiku T, Kume H. A case of miliary tuberculosis following transurethral surgery and prostate biopsy after intravesical Bacillus Calmette–Guerin immunotherapy. IJU Case Rep. 2021; 5: 45-47. 
  40. Yoshimura N, Homma Y, Tomoe H, Otsuka A, Kitta T, Masumori N, Akiyama Y, Niimi A, Mitsui T, Nanri M, Namima T, Takei M, Yamaguchi A, Sekiguchi Y, Kajiwara M, Kobayashi S, Ameda K, Ohashi Y, Sakamoto S, Muraki O, Shishido T, Kageyama S, Kokura K, Okazoe H, Yamanishi T, Watanabe T, Uno T, Ohinata A, Ueda T. Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: A multicenter, randomized, double-blind, placebo-controlled, clinical study. Int J Urol. 2021; 28: 545-553.
  41. Miyakawa J, Kawai T, Makino K, Akiyama Y, Yamada Y, Nakamura M, Sato Y, Yamada D, Suzuki M, Kume H. Impact of age, body mass index, and renal function for severe hypotension caused by oral 5-aminolevulinic acid administration in patients undergoing transurethral resection of bladder tumor. Photodiagnosis Photodyn Ther. 2021; 33: 102179.
  42. Takemura K, Kawai T, Sato Y, Miyakawa J, Taguchi S, Akiyama Y, Yamada Y, Nakamura M, Yamada D, Suzuki M, Nakagawa T, Kume H. Impact of initial computed tomography findings on management of atypical urinary cytology of the upper urinary tract. Urol Int. 2021; 105: 1-5.
  43. Endo K, Yamada D, Suzuki M, Kawai T, Sato Y, Nakamura M, Yamada Y, Akiyama Y, Kato A, Kume H. Hypertensive Crisis During Surgery of Solitary Ginger like Bladder Tumor with Retained Submucosal Blood Vessels. Journal of Medical and Advanced Clinical Case Reports (J Med Adv Clin Case Rep). 2020; 2: 01-04. 
  44. Makino K, Kawai T, Sato Y, Makise N, Morishige T, Oshina T, Akiyama Y, Yamada Y, Nakamura M, Yamada D, Suzuki M, Ushiku T, Kume H. Implantation of colorectal cancer from the upper urinary tract to the bladder via urine. Clin Oncol Res. 2020; 3: 1-3.
  45. Watanabe D, Akiyama Y*, Niimi A, Nomiya A, Yamada Y, Sato Y, Nakamura M, Kawai T, Yamada D, Suzuki M, Igawa Y, Kume H, Homma Y. Clinical characterization of interstitial cystitis/bladder pain syndrome in women based on the presence or absence of Hunner lesions and glomerulations. Low Urin Tract Symptoms. 2020; 13: 139-143.
    [Top Cited Article 2021-2022 in Lower Urinary Tract Symptoms]
  46. Akiyama Y* and Homma Y. Immunomodulating therapies for interstitial cystitis/bladder pain syndrome. Curr Bladder Dysfunct Rep. 2020; :1-6.
  47. Homma Y, Akiyama Y, Tomoe H, Furuta A, Ueda T, Maeda D, Lin AT, Kuo HC, Lee MH, Oh SJ, Kim JC, Lee KS. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int J Urol. 2020; 27: 578-589.
  48. Akiyama Y*, Luo Yi, Hanno PM, Maeda D, Homma Y. Interstitial cystitis/bladder pain syndrome: The Evolving Landscape, Animal Models, and Future Perspectives. Int J Urol. 2020; 27: 491-503.
    [Top Cited Article 2020-2021 in International Journal of Urology]
    [Most Cited Article 2021-2022 in International Journal of Urology]
    [Most Cited Article 2022-2023 in International Journal of Urology]
  49. Akiyama Y. Update on the pathophysiology of interstitial cystitis/bladder pain syndrome. Current Bladder Dysfunction Reports. 2020; 15: 1-8.
  50. Matsui H, Kawai T, Sato Y, Ishida J, Kadowaki H, Akiyama Y, Yamada Y, Nakamura M, Yamada D, Akazawa H, Suzuki M, Komura I, Kume H. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma. Int Heart J. 2020; 61: 1070-1074.
  51. Oshina T, Kawai T, Sato Y, Miyakawa J, Miyama Y, Makino K, Akiyama Y, Yamada Y, Nakamura M, Yamada D, Suzuki M, Ushiku T, Kume H. Inverted papilloma of the urinary bladder shows fluorescence on photodynamic diagnosis using 5-aminolevulinic acid. Photodiagnosis Photodyn Ther. 2020; 30: 1017666.
  52. Homma Y, Akiyama Y, Niimi A, Nomiya A, Igawa Y. Classification, Characterization, and Sub-Grouping of Interstitial Cystitis. Curr Bladder Dysfunct Rep. 2019; 14: 294-300.
  53. Akiyama Y*, Maeda D, Katoh H, Morikawa T, Niimi A, Nomiya A, Sato Y, Kawai T, Goto A, Fujimura T, Fukuhara H, Nakagawa T, Igawa Y, Ishikawa S, Fukayama M, Kume H, Homma Y. Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies. J Urol. 2019; 202: 290-300.
  54. Akiyama Y *and Hanno P. Phenotyping of interstitial cystitis/bladder pain syndrome. Int J Urol. 2019; 26 (Suppl. 1): 17-19. (
    [TOP DOWNLOADED PAPER 2018-2019 in International Journal of Urology]
  55. Akiyama Y*, Homma Y and Maeda D*. Pathology and terminology of interstitial cystitis/bladder pain syndrome: A review. Histol Histopathol. 2019; 34: 25-32.   
  56. Akiyama Y*, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Igawa Y, and Homma Y. Extent of Hunner lesions: The relationships with symptom severity and clinical parameters in Hunner type interstitial cystitis patients. Neurourol Urodyn. 2018; 37: 1441-1447.
  57. Akiyama Y, Maeda D, Morikawa T, Niimi A, Nomiya A, Yamada Y, Igawa Y, Goto A, Fukayama M and Homma Y. Digital Quantitative Analysis of Mast Cell Infiltration in Interstitial Cystitis. Neurourol Urodyn. 2018; 37: 650-657.
  58. Niimi A, Igawa Y, Aizawa N, Honma T, Nomiya A, Akiyama Y, Kamei J, Fujimura T, Fukuhara H, Homma Y. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. Neurourol Urodyn. 2018; 37: 1113-1119.
  59. Ichihara K, Aizawa N, Akiyama Y, Kamei J, Masumori N, Andersson KE, Homma Y, Igawa Y. Toll-like receptor 7 is overexpressed in the bladder of Hunner type interstitial cystitis and its activation in the mouse bladder can induce cystitis and bladder pain. Pain. 2017; 158: 1538-1545.
  60. Akiyama Y*, Morikawa T, Maeda D, Shintani Y, Niimi A, Nomiya A, Nakayama A, Igawa Y, Fukayama M, Homma Y. Increased CXCR3 Expression of Infiltrating Plasma Cells in Hunner Type Interstitial Cystitis. Sci Rep. 2016; 6: 28652.
  61. Maeda D*, Akiyama Y*, Morikawa T, Kunita A, Ota Y, Katoh H, Niimi A, Nomiya A, Ishikawa S, Goto A, Igawa Y, Fukayama M, Homma Y. Hunner-Type (Classic) Interstitial Cystitis: A Distinct Inflammatory Disorder Characterized by Pancystitis, with Frequent Expansion of Clonal B-Cells and Epithelial Denudation. PLoS One. 2015; 10: e0143316.
    [Top 10% most cited PLOS ONE paper published in 2015]
  62. Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, Nakagawa T, Fukuhara H, Kume H, Igawa Y, Homma Y. Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. Int J Urol. 2015; 22: 835-41.
  63. Kamei J, Furuta A, Akiyama Y, Niimi A, Ichihara K, Fujimura T, Fukuhara H, Kume H, Homma Y, Igawa Y. Video-urodynamic effects of mirabegron, a β (3)-adrenoceptor agonist, in patients with low-compliance bladder. Int J Urol. 2015; 22: 956-61.

スタッフ一覧に戻る

スタッフ・認定医・専門医紹介

泌尿器科教室の成り立ち

研究・業績

お問い合わせcontact

信州大学 医学部 泌尿器科学教室への研修・見学・医局へのお問い合わせはこちら